SEC Company Response from KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514) (KPRX) — Oct 2, 2014
KIORA PHARMACEUTICALS INC (KPRX) (CIK 0001372514)
Date: Oct. 2, 2014 · CIK: 0001372514 · Accession: 0001144204-14-059349
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-197725
Letter
AEGIS CAPITAL CORP.
810 Seventh Avenue
11th Floor
New York, NY 10019
October 2, 2014
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: Eyegate Pharmaceuticals, Inc.
Withdrawal of Acceleration Request- Registration Statement, as amended on Form S-1 (File No. 333-197725)
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence via EDGAR on September 30, 2014, in which we, as representative of the several underwriters of Eyegate Pharmaceuticals, Inc.’s proposed public offering of common stock, joined Eyegate Pharmaceuticals, Inc.’s request for acceleration of the effective date of the above-referenced Registration Statement for Thursday, October 2, 2014, at 5:00 p.m. Eastern Time. Eyegate Pharmaceuticals, Inc. is no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
Very truly yours,
AEGIS CAPITAL CORP.
Show Raw Text
CORRESP
1
filename1.htm
AEGIS CAPITAL CORP.
810 Seventh Avenue
11th Floor
New York, NY 10019
October 2, 2014
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re:
Eyegate Pharmaceuticals, Inc.
Withdrawal of Acceleration Request- Registration Statement,
as amended on Form S-1 (File No. 333-197725)
Ladies and Gentlemen:
Reference is made to our letter, filed
as correspondence via EDGAR on September 30, 2014, in which we, as representative of the several underwriters of Eyegate Pharmaceuticals,
Inc.’s proposed public offering of common stock, joined Eyegate Pharmaceuticals, Inc.’s request for acceleration of
the effective date of the above-referenced Registration Statement for Thursday, October 2, 2014, at 5:00 p.m. Eastern Time. Eyegate
Pharmaceuticals, Inc. is no longer requesting that such Registration Statement be declared effective at this time and we hereby
formally withdraw our request for acceleration of the effective date.
Very truly yours,
AEGIS CAPITAL CORP.
As Representative of the several Underwriters
By:
/s/ Eugene Terracciano
Name:
Eugene Terracciano
Title:
Director of Compliance